COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease

The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the causative factor behind the 2019 global coronavirus pandemic (COVID-19). The main protease, known as M(pro), is encoded by the viral genome and is essential for viral replication. It has also been an effective target for drug de...

Descripción completa

Detalles Bibliográficos
Autores principales: Kronenberger, Thales, Laufer, Stefan A., Pillaiyar, Thanigaimalai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Keynote
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074736/
https://www.ncbi.nlm.nih.gov/pubmed/37028502
http://dx.doi.org/10.1016/j.drudis.2023.103579
_version_ 1785019800171315200
author Kronenberger, Thales
Laufer, Stefan A.
Pillaiyar, Thanigaimalai
author_facet Kronenberger, Thales
Laufer, Stefan A.
Pillaiyar, Thanigaimalai
author_sort Kronenberger, Thales
collection PubMed
description The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the causative factor behind the 2019 global coronavirus pandemic (COVID-19). The main protease, known as M(pro), is encoded by the viral genome and is essential for viral replication. It has also been an effective target for drug development. In this review, we discuss the rationale for inhibitors that specifically target SARS-CoV-2 M(pro). Small molecules and peptidomimetic inhibitors are two types of inhibitor with various modes of action and we focus here on novel inhibitors that were only discovered during the COVID-19 pandemic highlighting their binding modes and structures.
format Online
Article
Text
id pubmed-10074736
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-100747362023-04-05 COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease Kronenberger, Thales Laufer, Stefan A. Pillaiyar, Thanigaimalai Drug Discov Today Keynote The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the causative factor behind the 2019 global coronavirus pandemic (COVID-19). The main protease, known as M(pro), is encoded by the viral genome and is essential for viral replication. It has also been an effective target for drug development. In this review, we discuss the rationale for inhibitors that specifically target SARS-CoV-2 M(pro). Small molecules and peptidomimetic inhibitors are two types of inhibitor with various modes of action and we focus here on novel inhibitors that were only discovered during the COVID-19 pandemic highlighting their binding modes and structures. Elsevier Ltd. 2023-06 2023-04-05 /pmc/articles/PMC10074736/ /pubmed/37028502 http://dx.doi.org/10.1016/j.drudis.2023.103579 Text en © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Keynote
Kronenberger, Thales
Laufer, Stefan A.
Pillaiyar, Thanigaimalai
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
title COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
title_full COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
title_fullStr COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
title_full_unstemmed COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
title_short COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
title_sort covid-19 therapeutics: small-molecule drug development targeting sars-cov-2 main protease
topic Keynote
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074736/
https://www.ncbi.nlm.nih.gov/pubmed/37028502
http://dx.doi.org/10.1016/j.drudis.2023.103579
work_keys_str_mv AT kronenbergerthales covid19therapeuticssmallmoleculedrugdevelopmenttargetingsarscov2mainprotease
AT lauferstefana covid19therapeuticssmallmoleculedrugdevelopmenttargetingsarscov2mainprotease
AT pillaiyarthanigaimalai covid19therapeuticssmallmoleculedrugdevelopmenttargetingsarscov2mainprotease

Ejemplares similares